Exactech Knee and Hip Implant Litigation: MDL 3044 Status

The Exactech polyethylene litigation is a group of federal product liability cases about knee, hip and ankle implants whose plastic components are alleged to have degraded and worn out early. The cases are consolidated as MDL 3044 in the Eastern District of New York before Judge Nicholas G. Garaufis. The Judicial Panel on Multidistrict Litigation counted 1,838 actions pending as of October 1, 2026, out of 1,847 filed over the life of the proceeding. The reviewed court orders do not set a trial date, report a verdict, or describe a settlement.

Which devices the litigation covers

The court’s direct filing order limits the MDL to personal injury cases alleging total joint replacement failure and injury from accelerated polyethylene wear in three device groups. The first is the Optetrak, Optetrak Logic and Truliant total knee replacement systems. The second is Exactech total hip replacement systems implanted with GXL polyethylene liners and certain MCS and Acumatch conventional ultra-high-molecular-weight polyethylene liners. The third is the Vantage total ankle replacement system (amended direct filing order).

The transfer order describes the two events that prompted the consolidation. On June 28, 2021, Exactech issued a product safety alert about the clinical performance of the polyethylene liner used in its Connexion GXL hip systems. In August 2021, the company initiated a recall of knee and ankle polyethylene inserts because they had been packaged “in out-of-specification vacuum bags that are oxygen resistant but do not contain a secondary oxygen barrier of ethylene vinyl alcohol” (transfer order).

What the FDA recall records show

The FDA’s device enforcement database contains separate recall records for the hip and knee products. Each is a voluntary, firm-initiated action, and each was classified as Class II.

• Connexion GXL hip liners. Recall Z-2119-2021 lists an initiation date of June 29, 2021 and a quantity of 89,050 units. The stated reason is a risk of edge loading and premature prosthesis wear “in a specific subset of patients with certain implant configurations and surgical implant positioning” (FDA report Z-2119-2021).
• Optetrak Logic knee inserts. Recall Z-0021-2022 lists an initiation date of August 30, 2021 and 109,787 devices. The stated reason is that the inserts “were packaged in vacuum bags that lacked an additional oxygen barrier layer.” The record notes an expansion initiated February 7, 2022 (FDA report Z-0021-2022). The Panel’s order gives August 31, 2021 as the date of that recall.
• GXL acetabular hip liners. Recall Z-1728-2022 lists an initiation date of August 11, 2022 and 11,143 devices. The stated reason is that liners “packaged in non-conforming bags, may adversely impact the device and contribute to accelerated wear” (FDA report Z-1728-2022).

The Panel described the February 2022 expansion as covering “all knee and ankle arthroplasty polyethylene inserts packaged in non-conforming bags regardless of label or shelf life,” and described the August 2022 expansion as affecting approximately 40,000 moderately cross-linked and conventional polyethylene acetabular hip liners (transfer order). A Class II classification is the agency’s designation, not a court finding that any implant caused an injury.

What is established vs. what is alleged

Established by the court record

• The consolidation exists. The Panel created MDL 3044 on October 7, 2022 and assigned it to Judge Garaufis in the Eastern District of New York. The motion before the Panel covered 27 actions in 11 districts plus 48 potentially related actions (transfer order).
• The case count is published. The Panel’s October 1, 2026 report lists 1,838 actions pending and 1,847 filed (JPML report).
• Direct filing is allowed. Under the amended direct filing order, a plaintiff whose case would be transferred as a tag-along may file directly in the Eastern District of New York. The order stops the running of limitations and repose periods for those filings and provides that, when the MDL proceedings end, directly filed cases will be transferred to the district the plaintiff designated, except cases selected to be tried as bellwether trials in the Eastern District (amended direct filing order).
• The TPG entities were dismissed. On March 7, 2024, the court granted a motion to dismiss by TPG, Inc. and affiliated entities that plaintiffs had sued on veil-piercing and successor liability theories. The dismissal applied to cases from 18 states; the court reserved judgment on cases from Missouri and Wyoming. The court found that the complaint did not plead the three elements of veil-piercing under Florida law (March 7, 2024 order).
• The individual filings are numerous. The March 2024 order refers to “more than 1,400 Short-Form Complaints in individual cases that are being coordinated before this court” (March 7, 2024 order).

Alleged in the complaints

The Panel summarized the plaintiffs’ theory in the transfer order. Plaintiffs allege that “oxidation of the moderately cross-linked polyethylene used in the Exactech hip, knee and ankle devices causes inflammatory responses when implanted, generates polyethylene debris, crack, and loosen the device, all of which in turn requires revision surgery.” They also allege that their knee or hip replacement devices “failed prematurely because of degradation of the device’s polyethylene component, which resulted in the premature removal (or planned removal) of the prosthesis at issue” (transfer order).

The March 2024 order described the same theory at greater length, including the assertion that the manufacturing and packaging processes made the implants “more reactive to the environment and susceptible to oxidative stress.” Those passages recite the allegations. The order decided a motion to dismiss the TPG entities; it did not find that any implant failed or caused an injury.

Where the claims stand procedurally

An MDL is not a trial and not a class action. It consolidates pretrial proceedings, mainly discovery and expert challenges, before one judge, while each plaintiff keeps an individual case. The difference is explained in MDL versus class action.

MDL 3044 remains on the Panel’s pending list. The October 2026 count of 1,838 pending against 1,847 filed leaves a difference of nine actions, which means nearly every case ever filed in the proceeding is still open. The reviewed orders do not set a bellwether trial date, report a verdict, or describe mediation or a settlement. The March 2024 dismissal order is the most recent substantive ruling in the reviewed record.

Other device dockets follow the same structure, including the Paragard IUD litigation and the Covidien hernia mesh litigation. The hernia mesh litigation overview covers a separate mesh docket, and the medical device litigation section collects the related articles.

Key dates

• June 28, 2021: Exactech issues a product safety alert about the Connexion GXL hip liner.
• June 29, 2021: The FDA record for the Connexion GXL hip liner recall lists its initiation date.
• August 30, 2021: The FDA record lists the initiation of the knee and ankle insert recall (the Panel’s order gives August 31).
• February 7, 2022: Exactech expands the knee and ankle insert recall.
• August 11, 2022: The FDA record lists the initiation of the expanded GXL hip liner recall.
• October 7, 2022: The Panel creates MDL 3044 and assigns Judge Garaufis.
• October 25, 2022: The court enters Practice and Procedure Order No. 1.
• January 11, 2023: The court enters the amended direct filing order.
• March 7, 2024: The court dismisses the TPG entities from cases in 18 states.
• October 1, 2026: The Panel reports 1,838 actions pending and 1,847 filed.

What this does not establish

Nothing in the reviewed record establishes that any Exactech implant caused a particular patient’s injury. The reviewed orders contain no trial date, verdict, or approved settlement. The FDA recall records state the firm’s reasons for the recalls and the agency’s classifications; they do not decide causation. The dismissal of the TPG entities turned on the sufficiency of the pleadings about corporate liability, not on the merits of the implant claims. A pending case count measures filings, not the strength or value of any claim.

Frequently asked questions

Is this a class action?

No. MDL 3044 is a multidistrict proceeding that consolidates pretrial proceedings in individual personal injury cases. Each plaintiff remains the owner of an individual case, and the Panel’s transfer order does not create a class or a common fund.

Has a court found that the implants cause injury?

No. The reviewed orders address case management, direct filing and the sufficiency of pleadings against the TPG entities. None contains a causation finding, and the March 2024 order recites the plaintiffs’ theory as an allegation.

Is there a settlement?

No settlement appears in the reviewed court orders or the FDA records. The Panel’s October 2026 count shows the docket still active, with 1,838 actions pending. Readers should check the docket before relying on reports of one.

Does a recall mean the implant was defective?

No. A recall is a firm-initiated action that the FDA classifies, and the records here state the company’s reasons for removing or correcting the products. A recall classification is not a judicial finding of defect or causation, and it does not by itself establish that any patient was injured.

Sources

1. United States Judicial Panel on Multidistrict Litigation: “MDL Statistics Report - Distribution of Pending MDL Dockets by District” (link, accessed 2026-10-18)
2. United States Judicial Panel on Multidistrict Litigation: “Transfer Order, In re Exactech Polyethylene Orthopedic Products Liability Litigation, MDL No. 3044” (link, accessed 2026-10-18)
3. United States District Court for the Eastern District of New York: “Practice and Procedure Order No. 1, In re Exactech Polyethylene Orthopedic Products Liability Litigation, No. 22-md-03044 (E.D.N.Y. Oct. 25, 2022)” (link, accessed 2026-10-18)
4. United States District Court for the Eastern District of New York: “Amended Practice and Procedure Order No. 2 (Direct Filing), In re Exactech Polyethylene Orthopedic Products Liability Litigation, No. 22-md-03044 (E.D.N.Y. Jan. 11, 2023)” (link, accessed 2026-10-18)
5. United States District Court for the Eastern District of New York: “Memorandum and Order on the TPG Defendants’ Motion to Dismiss, In re Exactech Polyethylene Orthopedic Products Liability Litigation, No. 22-md-03044 (E.D.N.Y. Mar. 7, 2024)” (link, accessed 2026-10-18)
6. U.S. Food and Drug Administration: “Device Enforcement Report Z-2119-2021, Exactech Connexion GXL Acetabular Liners” (link, accessed 2026-10-18)
7. U.S. Food and Drug Administration: “Device Enforcement Report Z-0021-2022, Exactech Optetrak Logic Polyethylene Tibial Inserts” (link, accessed 2026-10-18)
8. U.S. Food and Drug Administration: “Device Enforcement Report Z-1728-2022, Exactech GXL Acetabular Liners” (link, accessed 2026-10-18)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.